Around 40% of drugs covered by the UK’s voluntary drug revenue rebate system, the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), are generics and biosimilars. Because of this, the British Generics Manufacturers Association (BGMA) wants in on deliberations just like the organization representing branded medications, the Association of the British Pharmaceutical Industry (ABPI).
According to Phil Taylor, “The BGMA says its members are being forced to contribute to the clawback scheme without any input into how it is set up and operated, risking the viability of an industry that already subsists on thin margins as competition in the market is high, keeping prices low.”
To read more, click here.
(Source: Pharmaphorum, April 24th, 2023)